share_log

eFFECTOR Therapeutics | 8-K: eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

eFFECTOR Therapeutics | 8-K: Current report

eFFECTOR Therapeutics | 8-K：重大事件
美股SEC公告 ·  2024/03/26 04:15

Moomoo AI 已提取核心訊息

On March 25, 2024, eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported a net loss of $9.1 million for the quarter and $35.8 million for the full year. Despite the losses, eFFECTOR highlighted significant progress in its clinical programs, including the expected early April 2024 release of topline data from the Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC). Additionally, the company reported a median progression-free survival of 7.4 months in a cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients with ER+ breast cancer. eFFECTOR also received U.S. FDA Fast Track designation for zotatifin in this patient population. The company raised $15.0 million in gross proceeds from registered direct financing, extending its cash runway into the first quarter of 2025. The financial report detailed R&D and G&A expenses, along with other income and expenses, and provided an update on the company's cash position and guidance.
On March 25, 2024, eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company reported a net loss of $9.1 million for the quarter and $35.8 million for the full year. Despite the losses, eFFECTOR highlighted significant progress in its clinical programs, including the expected early April 2024 release of topline data from the Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC). Additionally, the company reported a median progression-free survival of 7.4 months in a cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients with ER+ breast cancer. eFFECTOR also received U.S. FDA Fast Track designation for zotatifin in this patient population. The company raised $15.0 million in gross proceeds from registered direct financing, extending its cash runway into the first quarter of 2025. The financial report detailed R&D and G&A expenses, along with other income and expenses, and provided an update on the company's cash position and guidance.
2024年3月25日，臨床階段的生物製藥公司Effector Therapeutics, Inc. 公佈了截至2023年12月31日的第四季度和全年財務業績。該公司報告本季度淨虧損910萬美元，全年淨虧損3580萬美元。儘管虧損，但Effector還是強調了其臨床項目的重大進展，包括預計於2024年4月初發布的托米沃舍替布聯合pembrolizumab治療非小細胞肺癌（NSCLC）的2b期KICKSTART試驗的主要數據。此外，該公司報告稱，在評估佐他替芬與氟維司朗和阿貝馬西利布聯合治療的ER+乳腺癌患者中，無進展存活率中位數爲7.4個月。Effector還獲得了美國食品藥品管理局對該患者群體中佐他替芬的快速通道認定。該公司通過註冊直接融資籌集了1,500萬澳元的總收益，將其現金流延至2025年第一季度。財務報告詳細介紹了研發和併購費用以及其他收入和支出，並提供了公司的最新現金狀況和指導。
2024年3月25日，臨床階段的生物製藥公司Effector Therapeutics, Inc. 公佈了截至2023年12月31日的第四季度和全年財務業績。該公司報告本季度淨虧損910萬美元，全年淨虧損3580萬美元。儘管虧損，但Effector還是強調了其臨床項目的重大進展，包括預計於2024年4月初發布的托米沃舍替布聯合pembrolizumab治療非小細胞肺癌（NSCLC）的2b期KICKSTART試驗的主要數據。此外，該公司報告稱，在評估佐他替芬與氟維司朗和阿貝馬西利布聯合治療的ER+乳腺癌患者中，無進展存活率中位數爲7.4個月。Effector還獲得了美國食品藥品管理局對該患者群體中佐他替芬的快速通道認定。該公司通過註冊直接融資籌集了1,500萬澳元的總收益，將其現金流延至2025年第一季度。財務報告詳細介紹了研發和併購費用以及其他收入和支出，並提供了公司的最新現金狀況和指導。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間